ArticleDiabetologia2008
Inhibition of c-jun N terminal kinase (JNK) improves functional beta cell mass in human islets and leads to AKT and glycogen synthase kinase-3 (GSK-3) phosphorylation.
Article in Diabetologia, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 77 citations in OpenAlex.
- A nucleic acid regulation strategy under mechanical stress for intervertebral disc degeneration treatment.Bioactive materials · 2026Article
- JNK and p53 cause human and mouse β cell death during excessive unfolded protein response.The Journal of clinical investigation · 2026Article
- Long-term storage, cryopreservation, and culture of isolated human islets: a systematic review.Frontiers in transplantation · 2025Review
- JNK1 ablation improves pancreatic β-cell mass and function in db/db diabetic mice without affecting insulin sensitivity and adipose tissue inflammation.FASEB bioAdvances · 2021Article
- Regulation of c-Jun NHJournal of clinical medicine · 2019Review
- Cdc42 Promotes ADSC-Derived IPC Induction, Proliferation, And Insulin Secretion Via Wnt/β-Catenin Signaling.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019Article
- Modified cell-permeable JNK inhibitors efficiently prevents islet apoptosis and improves the outcome of islet transplantation.Scientific reports · 2018Article
- ERK5 plays an essential role in gestational beta-cell proliferation.Cell proliferation · 2018Article
- Protective effects of asiatic acid in a spontaneous type 2 diabetic mouse model.Molecular medicine reports · 2017Article
- Human islet xenotransplantation in rodents: A literature review of experimental model trends.Clinics (Sao Paulo, Brazil) · 2017Review
- JNK at the crossroad of obesity, insulin resistance, and cell stress response.Molecular metabolism · 2017Review
- Article
- The Temporal Regulation of S Phase Proteins During GAdvances in experimental medicine and biology · 2017Review
- Islet Culture/Preservation Before Islet Transplantation.Cell medicine · 2015Review
- Regulation of the JNK3 signaling pathway during islet isolation: JNK3 and c-fos as new markers of islet quality for transplantation.PloS one · 2014Article
- Article
- Transdisciplinary approach to restore pancreatic islet function.Immunologic research · 2013Review
- Cyclodextrin protects podocytes in diabetic kidney disease.Diabetes · 2013Article
- In vivo JNK activation in pancreatic β-cells leads to glucose intolerance caused by insulin resistance in pancreas.Diabetes · 2013Article
- Withaferin A inhibits pro-inflammatory cytokine-induced damage to islets in culture and following transplantation.Diabetologia · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
aims/hypothesisActivation of c-jun N-terminal kinase (JNK) has been described in islet isolation and engraftment, making JNK a key target in islet transplantation. The objective of this study was to investigate if JNK inhibition with a cell-permeable TAT peptide inhibitor (L-JNKI) protects functional beta cell mass in human islets and affects AKT and its substrates in islet cells.
methodsThe effect of L-JNKI (10 micromol/l) on islet count, mitochondrial membrane potential, glucose-stimulated insulin release and phosphorylation of both AKT and its substrates, as well as on reversal of diabetes in immunodeficient diabetic Nu/Nu mice was studied.
resultsIn vitro, L-JNKI reduced the islet loss in culture and protected from cell death caused by acute cytokine exposure. In vivo, treatment of freshly isolated human islets and diabetic Nu/Nu mice recipients of such islets resulted in improved functional beta cell mass. We showed that L-JNKI activates AKT and downregulates glycogen synthase kinase-3 beta (GSK-3B) in human islets exposed to cytokines, while other AKT substrates were unaffected, suggesting that a specific AKT/GSK-3B regulation by L-JNKI may represent one of its mechanisms of cytoprotection. CONCLUSIONS/
interpretationIn conclusion, we have demonstrated that targeting JNK in human pancreatic islets results in improved functional beta cell mass and in the regulation of AKT/GSK3B activity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.